CD BioSciences Launches Comprehensive Anti-Aging Drug Development Platform
TL;DR
CD BioSciences offers pharmaceutical companies a competitive edge with comprehensive anti-aging drug development services that accelerate R&D timelines and reduce entry barriers.
CD BioSciences provides a systematic anti-aging drug development process covering target verification, lead compound screening, preclinical models, pharmacology, pharmacokinetics, and safety evaluation.
This service advances anti-aging therapeutics that could extend healthy lifespans and improve quality of life for aging populations worldwide.
CD BioSciences uses diverse aging models including naked mole-rats and zebrafish to test drugs targeting pathways like mTOR and SIRT1.
Found this article helpful?
Share it with your network and spread the knowledge!
CD BioSciences has launched a comprehensive one-stop anti-aging drug development service package for pharmaceutical companies, research institutions, and academic investigators working on cutting-edge anti-aging therapeutics. This initiative addresses significant industry challenges by providing integrated support throughout the entire drug development cycle, from early discovery to preclinical stages.
The company's diversified anti-aging drug discovery services offer customized solutions across a wide range of targets and drug types. Key molecular targets covered include AMPK, mTOR, SIRT1, NF-κB, p53, and PI3K signaling pathways, which are closely associated with aging mechanisms. For drug types, the service encompasses mainstream anti-aging categories including senolytics, senomorphics, calorie restriction mimetics, autophagy inducers, anti-inflammatory drugs, antioxidants, telomerase activators, and mitochondrial modulators.
CD BioSciences' services extend to a complete preclinical development system covering multiple critical links to ensure scientific reliability. Anti-aging pharmacology services include both in vitro and in vivo evaluations to verify therapeutic efficacy. The company provides in vitro ADME services and in vivo pharmacokinetic services for early assessment of drug behaviors, along with in vitro toxicity testing, non-GLP toxicology, and safety pharmacology services that evaluate potential toxic effects on cardiovascular, respiratory, central nervous, and other key physiological systems.
As a specialized aging disease model CRO, CD BioSciences has built a comprehensive and customizable preclinical aging model platform. Model customization services cover four major categories: organ-specific aging models for skin, cardiac, liver, lung, kidney, and muscle; general aging models including cellular senescence models, yeast aging models, aging mouse/rat models, non-human primate aging models, and zebrafish aging models; longevity models featuring long-lived yeast strains, Drosophila, genetic mouse models, Fukomys mole-rat and naked mole-rat models; and aging-related disease models for neurodegenerative diseases, cardiovascular diseases, bone loss, respiratory diseases, eye diseases, sarcopenia, and progeria.
The launch of these integrated services aims to address the key challenges of lengthy timelines and high barriers to entry in anti-aging research and development. By combining cutting-edge technical platforms with industry-leading experience, CD BioSciences seeks to accelerate innovation in longevity therapeutics. The company's commitment to longevity and anti-aging research positions it to support global institutions in advancing anti-aging drug pipelines and transforming therapeutic approaches to aging-related conditions.
Curated from 24-7 Press Release
